- undefined
- undefined
- undefined
- undefined
-
- ¡Intentar construir su término de la búsqueda una a la vez, y ser tan específico como usted puede! Buscar el ejemplo del término: “tos crónica”.
- No incorporar los resultados múltiples tales como "anemia, tos crónica, pérdida de peso, vomitando" todos al mismo tiempo.
- Después de seleccionar su término de la búsqueda resulta una lista de diagnosis posibles será generada. Si la lista es demasiado larga, usted podrá enangostarla abajo incorporando términos adicionales.
- No incorporar los valores tales como "ritmo 110 del corazón" o "sodio 125", en lugar uso "taquicardia" o "hyponatremia".
Información de la droga para ENBREL (etanercept) For Subcutaneous Injection (Immunex Corp): INDICATIONS AND USAGE
- DESCRIPTION
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- WARNINGS
- OVERDOSAGE
- HOW SUPPLIED
- REFERENCES
- Medication GuideENBREL® (en-brel)(etanercept)
- Patient Instructions for UseENBREL® (en-brel)(etanercept)Single-use Prefilled Syringe
- Patient Instructions for UseENBREL® (en-brel)(etanercept)Multiple-use Vial
- Patient Instructions for UseENBREL® (en-brel)(etanercept)Single-use Prefilled SureClick™ Autoinjector
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - PREFILLED SYRINGE, 25 MG
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - PREFILLED SYRINGE, 50 MG
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - PREFILLED AUTOINJECTOR, 50 MG
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - VIAL, 25 MG
ENBREL® is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL® can be initiated in combination with methotrexate (MTX) or used alone.
ENBREL® is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.
ENBREL® is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL® can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
ENBREL® is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
ENBREL® is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Drug Information Provided by National Library of Medicine (NLM).